LM-061

Phase I dose escalation Main objectives: 1) Evaluate the safety and tolerability of LM-061 tablets in patients with advanced solid tumors; 2) Determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of LM-061 tablets in patients with advanced solid tumors; 3) Determine the Phase II recommended dose (RP2D). Secondary objectives: 1) Evaluate the pharmacokinetic characteristics of LM-061 tablets in patients with advanced solid tumors; 2) Evaluate the preliminary antitumor activity of LM-061 tablets in patients with advanced solid tumors; Phase II dose expansion Primary objectives: Evaluate the antitumor activity of LM-061 tablets in patients with c-MET abnormal EGFR-TKI-resistant non-small cell lung cancer, pulmonary sarcomatoid adenocarcinoma, papillary renal cell carcinoma, metastatic or locally advanced unresectable gastric adenocarcinoma, etc.; Secondary objectives: 1) Evaluate the safety and tolerability of LM-061 tablets in patients with c-MET abnormal EGFR-TKI-resistant non-small cell lung cancer, pulmonary sarcomatoid adenocarcinoma, papillary renal cell carcinoma, metastatic or locally advanced unresectable gastric adenocarcinoma, etc.; 2) Evaluate the pharmacokinetic characteristics of LM-061 tablets in patients with c-MET abnormal EGFR-TKI-resistant non-small cell lung cancer, pulmonary sarcomatoid adenocarcinoma, papillary renal cell carcinoma, metastatic or locally advanced unresectable gastric adenocarcinoma, etc.